#SFHS2613754AFrance adds ORGOVYX to the reimbursable medicines list
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
ORGOVYX 120 mg, a relugolix tablet supplied by Accord Healthcare France SAS, is added to France’s list of medicines reimbursed by social health insurance. The patient co-payment is removed for this product, meaning eligible patients can receive coverage without the usual patient share. Reimbursement applies only for the therapeutic indication covered by the marketing authorisation on the publication date. The change takes effect on the fourth day after publication in the Official Journal.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds ORGOVYX 120 mg to the list of medicines reimbursed by French social health insurance
- Removes the patient co-payment for this medicine
- Limits reimbursement to the approved therapeutic indication in force on the publication date
Obligations
What this law requires
French social health insurance reimbursement systems must include ORGOVYX 120 mg (relugolix), CIP 34009 303 280 0 2, supplied by Accord Healthcare France SAS, on the list of reimbursable pharmaceutical specialties.
Reimbursement for ORGOVYX 120 mg must be limited to the therapeutic indication stated in its marketing authorisation as of the publication date of the order.
The patient co-payment must be removed for reimbursed ORGOVYX 120 mg under Article R. 160-8 of the French Social Security Code.